

Introduction: Oral delivery is the most common administrated drug delivery path. However, oral administration of lipophilic drugs has some limitations: they have poor dose-response due to low and varied dissolution kinetics and oral bioavailability with sub-optimal dissolution within the aqueous gastrointestinal microenvironment. Therefore, there is a need for robust formulating methods that protect the drug until it reaches to its optimum absorption site, allowing its optimum pharmacological effects via increasing its intestinal permeation and bioavailability. Area covered: Herein, we provide insights on orally administered lipophilic drug delivery systems. The detailed description of the obstacles associated with the oral bioavailability of lipophilic drugs are also discussed. Following this, techniques to overcome these obstacles with much emphasis on optimal safety and efficacy are addressed. Newly designed ionic vibrational jet flow encapsulation technology has enormous growth in lipophilic drug delivery systems, which is discussed thereafter. Expert opinion: Researchers have shown interest in drug’s encapsulation. A combination of drug-bile acid and microencapsulation methods can be one promising strategy to improve the oral delivery of lipophilic drugs. However, the most critical aspect of this approach is the selection of bile acids, polymer, and encapsulation technology. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
| EMTREE drug terms: | alginic acidbile acidalginic aciddrugpolymer |
|---|---|
| EMTREE medical terms: | drug bioavailabilitydrug delivery systemdrug targetingdrug uptakeflowgelationionic gelation vibrational jet flowlipophilicitymicroencapsulationnanoencapsulationoral drug administrationReviewanimalbioavailabilitychemistrydrug delivery systemhumantechnology |
| MeSH: | Administration, OralAlginatesAnimalsBiological AvailabilityDrug Delivery SystemsHumansPharmaceutical PreparationsPolymersTechnology |
alginic acid, 28961-37-7, 29894-36-8, 9005-32-7, 9005-38-3;
Alginates; Pharmaceutical Preparations; Polymers
| Funding sponsor | Funding number | Acronym |
|---|---|---|
| Horizon 2020 Framework Programme See opportunities by H2020 | 872370 | H2020 |
H Al-Salami\u2019s work is partially supported by the European Union\u2019s Horizon 2020 SALSETH research and innovation programme under the Marie Sklodowska-Curie Grant agreement No. 872,370. H Al-Salami has been and is currently receiving funding from the Beijing Nat-Med Biotechnology Co. Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the paper apart from those disclosed.
Al-Salami, H.; Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth, WA, Australia;
© Copyright 2020 Elsevier B.V., All rights reserved.